razoxane has been researched along with aclarubicin in 4 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 3 (75.00) | 18.2507 |
2000's | 1 (25.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Jensen, PB; Sehested, M | 1 |
Anderson, H; Roberge, M | 1 |
Allan, WP; Creighton, AM; Fattman, CL; Hasinoff, BB; Kuschak, TI; Thampatty, P; Yalowich, JC | 1 |
Hansen, HF; Jensen, LH; Jensen, PB; Nitiss, JL; Rothenborg-Jensen, L; Schmidt, G; Sehested, M; Wessel, I | 1 |
4 other study(ies) available for razoxane and aclarubicin
Article | Year |
---|---|
Mapping of DNA topoisomerase II poisons (etoposide, clerocidin) and catalytic inhibitors (aclarubicin, ICRF-187) to four distinct steps in the topoisomerase II catalytic cycle.
Topics: Aclarubicin; Blotting, Western; Diterpenes; DNA Topoisomerases, Type II; Dose-Response Relationship, Drug; Etoposide; Humans; Lung Neoplasms; Razoxane; Tumor Cells, Cultured | 1996 |
Topoisomerase II inhibitors affect entry into mitosis and chromosome condensation in BHK cells.
Topics: Aclarubicin; Alkenes; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; Cell Cycle Proteins; Cell Line; Chromosomes; Cricetinae; DNA-Binding Proteins; Enzyme Inhibitors; Etoposide; G2 Phase; Guanine Nucleotide Exchange Factors; Kidney; Mitosis; Nuclear Proteins; Okadaic Acid; Phosphoprotein Phosphatases; Polyenes; Pyrones; Razoxane; Temperature; Thiobarbiturates; Topoisomerase II Inhibitors | 1996 |
Characterization of a Chinese hamster ovary cell line with acquired resistance to the bisdioxopiperazine dexrazoxane (ICRF-187) catalytic inhibitor of topoisomerase II.
Topics: Aclarubicin; Animals; CHO Cells; Cricetinae; DNA Topoisomerases, Type II; Drug Resistance; Ethylenediamines; Etoposide; Glycine; Mutation; Razoxane; Thiobarbiturates; Topoisomerase II Inhibitors; Verapamil | 1997 |
Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
Topics: Aclarubicin; Acridines; Antibiotics, Antineoplastic; Antineoplastic Agents; Biological Transport, Active; Cell Survival; Cross-Linking Reagents; DNA; DNA Damage; DNA Topoisomerases, Type II; Down-Regulation; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; In Vitro Techniques; Mutation; Podophyllotoxin; Polymerase Chain Reaction; Razoxane; Structure-Activity Relationship; Topoisomerase II Inhibitors; Tumor Cells, Cultured | 2001 |